News
As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a 2 billion-Swiss-francs luster to the once high-flying portfolio. The drug ...
Roche has secured a new FDA approval ... negative following a pathologist’s biopsy review. Enhertu received an FDA nod in HER2-ultralow breast cancer in late January, its seventh agency approval ...
Roche's Itovebi was the first PI3K inhibitor to get approved ... has an FDA green light as part of a combination regimen for patients with advanced HR-positive, HER2-negative breast cancer with ...
Roche RHHBY announced that the FDA has approved pipeline candidate, inavolisib, for the treatment of breast cancer ... based regimen was granted Priority Review by the FDA. It was also granted ...
Roche’s blockbuster vision for phosphoinositide ... Itovebi won US Food and Drug Administration (FDA) approval in this breast cancer indication based on INAVO120’s data late last year ...
The ‘558 patent covers a method developed at Penn’s Perelman School of Medicine ... outlined in the FDA approvals for four of Roche’s anti-ErbB antibodies in breast cancer: intravenous ...
The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant metastatic breast cancer. Among patients with liver-dominant metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results